Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

In the middle of a game night with friends, and looking for a simple and easy way to break the ice? Then a classic 21 Questions Game might be just what you are after—and we are here to help make it ...

If you have a Good Question you’d like us to try to answer, send it to goodquestion@wkyt.com. If you have a Good Question you’d like us to try to answer, send it ...